Nina S. Kjellson Sells 3,993 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Nina S. Kjellson sold 3,993 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $16.36, for a total transaction of $65,325.48. Following the completion of the sale, the director now directly owns 3,707,420 shares of the company’s stock, valued at $60,653,391.20. The trade was a 0.11 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Tyra Biosciences Stock Performance

Tyra Biosciences stock traded down $0.28 during midday trading on Tuesday, reaching $15.91. The company’s stock had a trading volume of 187,035 shares, compared to its average volume of 297,086. The firm has a market capitalization of $805.05 million, a PE ratio of -9.88 and a beta of 1.04. Tyra Biosciences, Inc. has a fifty-two week low of $12.34 and a fifty-two week high of $29.60. The stock’s 50 day simple moving average is $15.38 and its 200 day simple moving average is $19.20.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). Equities analysts predict that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have commented on TYRA. Bank of America raised Tyra Biosciences from a “neutral” rating to a “buy” rating and upped their price objective for the company from $22.00 to $31.00 in a research note on Friday, October 18th. UBS Group started coverage on Tyra Biosciences in a research note on Tuesday, January 7th. They set a “buy” rating and a $28.00 price target for the company. Wedbush reissued an “outperform” rating and issued a $28.00 price objective on shares of Tyra Biosciences in a research note on Friday, October 25th. Finally, HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Tyra Biosciences in a research note on Monday, January 13th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $30.50.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in TYRA. American Century Companies Inc. grew its stake in Tyra Biosciences by 582.9% in the 2nd quarter. American Century Companies Inc. now owns 170,283 shares of the company’s stock valued at $2,723,000 after acquiring an additional 145,346 shares during the last quarter. Perceptive Advisors LLC grew its position in shares of Tyra Biosciences by 50.5% in the second quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company’s stock valued at $16,108,000 after purchasing an additional 338,208 shares during the last quarter. Janus Henderson Group PLC purchased a new position in shares of Tyra Biosciences during the 3rd quarter worth approximately $24,994,000. Ensign Peak Advisors Inc acquired a new position in shares of Tyra Biosciences during the 2nd quarter worth approximately $3,047,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in Tyra Biosciences in the 3rd quarter valued at approximately $593,000. Institutional investors and hedge funds own 84.14% of the company’s stock.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.